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Historical Perspective on Non-Communicable Diseases
Worldwide
The blooming of incidence and prevalence of “prosperity diseases” among the broad layers of
modern day populations is rather novel phenomenon in demographic history of the human race
(1). Illnesses such as obesity (2), diabetes mellitus, hypertension, cerebrovascular and cardiovascular
consequences of atherosclerosis, renal insufficiency, mental disorders, and even cancer are closely
related to the increased longevity of most contemporary societies (3). In previous centuries, they
were mostly reserved for elite social groups enjoying rather luxurious life style. Vast majority of
citizens of the time were living in rural communities on the verge of poverty. Their structure of
morbidity even in Europe until late 19th century was dominated by burden of infectious diseases
and injury while neonatal and maternal mortality rates were huge. Industrial revolution led to the
growth of living standards, invention of vaccines, and antibiotics, and ultimately development of
organized publicly funded health systems. The prominent European health policy makers in the
19th century properly believed that effective public health measures will diminish huge burden
of infectious diseases. Consecutively, they expected that overall costs of medical care provision
should decrease substantially and ultimately reach plateau level. This second step turned out
to be a great miscalculation and a surprise. Like no time in written past, people began living
longer and healthier lives. But it happened at the cost. Simultaneously, from many industrialized
nations, evidence were accumulating of accelerated occurrence of non-communicable diseases.
Accomplishment of evidence-based medicine succeeded to control many of these initially incurable
diseases, thereby transforming them into life time disorders as in the typical cases of diabetes
and terminal renal insufficiency. Acute bacterial infections, dominating morbidity in the old days,
were usually successfully treated within few weeks. Unlike these, chronic illnesses were bringing
long-term burden for both the patients and the society. Malignant disorders with its complex
treatment strategies present particularly demanding medical conditions. Cancer leaves permanent
footprint in a life of a patient in terms of poor survival rates, decreased life quality, and working
ability.
Non-Communicable Diseases Expansion in Developing Countries
The ultimate demographic transition consisting of ascending portion of elderly, falling fertility
rates, and bold growth of median age within contemporary nations became broadly recognized as
population aging (4). Most of this transformation of morbidity and mortality structure happened
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in rich industrial countries of Western Europe, North America,
and Japan many decades ago. The same pattern of population
aging associated with huge incidence and prevalence rates of
major non-communicable diseases repeated on wider scale much
later in developing countries. The worldwide transformation of
public health landscape to the large extent is attributable to the
accelerated pace of globalization after the end of Cold War era
(5). Particularly interesting, current developments belong to the
economies responsible for most of global growth that are recog-
nized as the emerging markets. The countries whose reshaped
structure of morbidity is most likely to affect global health in
the future are definitely the BRICS [Brazil (6), Russia, India,
China, South Africa] (7). BRICS’s far extended long-term influ-
ence in health arena worldwide will be related to their mam-
moth sized populations. Their increased domestic demand for
medical technologies and medicines is already shaping invest-
ment strategies of major pharmaceutical and medicinal device
industries. Another significant issue is their bold foreign medical
assistance programs particularly targeted for emerging markets
of Sudanese Africa, Latin America, Central and South East Asia
(8). These leading countries are closely followed by a set of
smaller scale economies mostly marked as N-11 (Bangladesh,
Egypt, Indonesia, Iran, South Korea, Mexico, Nigeria, Pakistan,
the Philippines, Turkey, and Vietnam) (9). Very similar process is
simultaneously taking place in dynamically developing Southern
(10) and South-East Asian (11), Latin American, Eastern Euro-
pean (12), and Arab speaking MENA region (13). Eradication
of poverty currently taking place in these regions is coupled
with changed dietary habits (14) (higher salt and fat and lower
carbohydrate intake), wide spread tobacco abuse, and sedentary
life styles (15). The mentioned factors contributing to the grow-
ing burden of non-communicable diseases. It became obvious
that contribution of emerging markets and Third World coun-
tries to the global economic burden of NCDs will grow further.
It will, highly, likely, soon have greater share than the one of
established mature market economies (16). As basic assump-
tion of most forecasts remains the fact that such growth will
be dominated by developments in China (17) and India (18).
High toll of this unfortunate change for developing countries is
coupled impact of communicable and non-communicable dis-
eases (19). At the same time, many national health systems
throughout Asia and beyond expose poor responsiveness to
the NCDs related population needs. There seems to be serious
barriers in access to medical care and its affordability to the
ordinary citizens.
The increasing awareness on approaching of almost unbearable
burden of NCDs (20) led to the high profile United Nations
meeting on the subject in 2011 (21). Such UN gatherings are
so uncommon on health related topics that it happened only
once in past due to AIDS. NCDs recognized as the core global
health challenges were cardiovascular disorders, cancer, diabetes,
and chronic respiratory illness. These changes are beginning to
profoundly change the landscape of even the poorest countries
around the globe. So far, NCDs have already overarched burden
of infectious diseases and injury in terms of disability adjusted
life years, as well as work load and economic burden to the most
national health sectors (22).
Promising Cost-Effective Solutions for the
Future
The blossoming of prosperity disease did not happen suddenly.
It was a consequence of long chain of evolutionary events in
civil society development. We will mention only some of them
such as technological revolution, improved housing conditions,
sanitation and sewage disposal, public health successes in erad-
ication of major infectious diseases, policy efforts to tackle
hunger and starvation among the world’s poor, and ultimately
tobacco (23) and alcohol abuse (24). As its preconditions took
so long to be created, it is unlikely that we shall be able to
tackle NCD’s burden effectively in near future. Rich countries
as well as developing ones concluded that orchestrated efforts
will be needed in the international arena. World Health Orga-
nization has adopted a package of measures, whose implemen-
tation and progress are being monitored (25), broadly known
as “Global coordination mechanisms on NCDs” (26). As most
cost-effective and feasible measures were identified, control of
tobacco consumption to the targeted 5% consumers worldwide
until 2025 and reduction of salt intake by general populations
of at least 15% in the order of significance. These interven-
tions that were named “best buy” solutions offering best attain-
able compromise between the need for investment and out-
comes that will be gained (27). Promotion of active life style
and healthy diet, as well as other preventive and screening mea-
sures, comes at the second place. If such efforts are followed
closely by national authorities, WHO expects that these mea-
sures should achieve 25% reduction of NCD attributable prema-
ture mortality until 2025 (28). Many of the proposed strategies
were previously tested within a sound methodological framework
applied on a second largest emerging market of the America,
Mexico (29).
The most challenging issue for the emerging markets’ health
systems appears to be universal health coverage (30). These sys-
tems were built up on diverse historical legacies and should find
each one its own way to handle the upcoming pressure of prosper-
ity diseases coupled with accelerated population aging. Profound
transformation of current network of medical facilities in Third
World countries, as well as human capacity building, will be
forced to move priority from acute care toward complex, chronic
illnesses (31).
Growing Burden of NCDs Coincided with
Increasing Health Expenditures
As witnessed by current WHO estimates given in Table 1, we
may see that overall burden of non-communicable disease has
consolidated in some countries such as Russia recording even
slight decrease over the past decade. Nevertheless, leading emerg-
ing markets of China and India followed by a large distance in
absolute terms by Brazil and South Africa exhibited clear pattern
of increasing burden of NCDs expressed in terms of Years of
Life Lost, Years Lost due to Disability, and Disability-Adjusted
Life Year (DALY). According to WHO, NCDs attributable mor-
tality increased substantially among the same four countries with
notable promising exception of Russia. Russian partial success
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TABLE 1 | Non-communicable diseases burden-related indicators; WHO estimates for BRICS in 2000 and 2012; total health expenditure and out-of-pocket
health expenditure in terms of current international $ purchase power parity basis (source: Global Health Expenditure Database).
Brazil Russian
federation
India China South Africa
2000 2012 2000 2012 2000 2012 2000 2012 2000 2012
Population (millions) 174.5 198.6 146.8 143.2 1,042.3 1,236.7 1,287.7 1,384.8 44.8 52.4
Years of Life Lost [YLL (0000)]* 22,532 24,915 44,566 40,597 150,751 175,435 165,905 186,591 5,534 7,398
Years Lost due to Disability [YLD
(0000)]**
14,600 18,077 16,586 16,206 78,150 96,886 84,450 99,877 3,436 4,233
Disability-Adjusted Life Year [DALY
(0000)]***
37,132 42,992 61,152 56,803 228,901 272,321 250,355 286,468 8,970 11,631
Estimated deaths (0000) NCDs
caused, both sexes
777 978 1,819 1,801 4,579 5,869 6,839 8,577 176 264
Total expenditure on health (in million
current $ PPP)
$87,681 $220,240 $54,200 $211,008 $68,816 $193,969 $138,131 $664,644 $24,728 $51,458
Out of pocket expenditure (in million
current $PPP)
$33,277 $68,168 $16,242 $72,417 $46,771 $111,673 $81,469 $228,245 $3,227 $3,695
*WHO estimated Years of Life Lost (YLL) due to premature mortality NCDs caused, both sexes (0000).
**WHO estimated Years Lost due to Disability (YLD) for people living with NCDs or its consequences (0000).
***WHO estimated Disability-Adjusted Life Year (DALY) NCDs caused, both sexes (0000).
in containing but not decreasing toll of prosperity diseases over
2000–2012 observation period might be attributable to the strong
public health legacy of Soviet era as well as reform policies
implemented in recent past (32). The rates of hospital discharges
increased substantially in the emerging markets across the globe
following the increased presence of NCDs in the overall mor-
bidity and mortality structure. This was mainly the case with
clinical admissions that could be attributed to the malignant
disorders (33) and circulatory diseases (34), followed by chronic
obstructive pulmonary diseases (35) and diabetes (36). National
level spending on medicines indicated to treat these conditions
followed at the same pace, so entire regional pharmaceutical
markets adjusted to these changes as was the case in South
Eastern Europe (37). Extensive presence of chronic prosperity
illnesses supported stronger demand for medical imaging (38),
laboratory testing (39), outpatient visits, prescription and dispens-
ing of novel pharmaceuticals (40), surgical, radiation oncology
(41), and rehabilitation services. These phenomena were relying
on strengthened civil expectations for advanced medical tech-
nologies supported by growing living standards and domestic
consumption in BRICS markets. If we take into account seri-
ous challenge of home-based care for the disabled and growing
portion of elderly citizens with special needs, bold growth of
national health expenditures should have been predicted (42).
China is absolutely leading in terms of purchase power parity
of its health spending. Huge lag of all other major emerging
economies behind People’s Republic of China is most obvious
when compared to the India, rapidly developing nation of a similar
population size.
Catastrophic household expenditure presents particularly cru-
cial issue throughout the countries of Sudanese Africa with very
low incomes, whose medical care is dominantly supported by
out-of-pocket spending (43). This happens due to absence of
strong national health insurance funds whose revenues would
come out of mandatory taxation supported by governmental and
external financial sources. Huge, occasionally sevenfold growth of
out-of-patient expenditure is clearly visible among the top BRICS
markets. Such socioeconomic vulnerability seriously affects the
poor members of the community. This might be the crucial
issue for long-term affordability (44) of medical care to the ordi-
nary citizens because almost all of the emerging markets own
massive rural populations. Urbanization process, which began
in Europe in 18th century, is still rapidly evolving throughout
Asia, Africa, and Latin America (45). Extensive development of
medical facilities network covering remote areas will remain one
of the key difficulties for national governments. This is worsened
by inevitable concentration of most professional staff in large
cities with much more rewarding personal career opportunities.
The primary goal for the future of these health systems wiil
be provision of accessible medical care. It should have decent
quality supported by universal health insurance coverage and
full reimbursement of at least essential medicines. The speed of
economic growth, political stability, and effectiveness of health
reforms remain highly diverse among the top 20 emerging mar-
kets. Some global forecasting agencies as well as international
financial organizations were pointing out that some smaller scale
N-11 economies were top performers on some criteria. Never-
theless, the prevailing consensus is that BRICS (46) health care
markets will inevitably outpace all others and remainwell ahead of
their competition shaping the global health challenges in the first
half of 21st century.
Acknowledgments
The Ministry of Education Science and Technological Develop-
ment of the Republic of Serbia has funded this study through
Grant OI 175014. Publication of results was not contingent to
Ministry’s censorship or approval.
Frontiers in Public Health | www.frontiersin.org April 2015 | Volume 3 | Article 653
Jakovljevic and Milovanovic Non-communicable diseases in BRICS nations
References
1. KuhD, Ben-ShlomoY.A Life Course Approach to Chronic Disease Epidemiology.
New York, NY: Oxford University Press (2004).
2. Chopra M, Galbraith S, Darnton-Hill I. A global response to a global prob-
lem: the epidemic of overnutrition. Bull World Health Organ (2002) 80(12):
952–8.
3. Jakovljevic M, Laaser U. Long term population aging 1950-2010 in seven-
teen transition countries in the wider region of South East Europe. SEEJPH
(2015) 3. doi:10.12908/SEEJPH-2014-42
4. Ogura S, Jakovljevic M. Health financing constrained by population aging –
an opportunity to learn from Japanese experience. Ser J Exp Clin Res (2014)
15:175–81. doi:10.2478/SJECR
5. Beaglehole R, Yach D. Globalisation and the prevention and control of non-
communicable disease: the neglected chronic diseases of adults. Lancet (2003)
362(9387):903–8. doi:10.1016/S0140-6736(03)14335-8
6. Schmidt MI, Duncan BB, Menezes AM, Monteiro CA, Barreto SM, Chor
D, et al. Chronic non-communicable diseases in Brazil: burden and current
challenges. Lancet (2011) 377(9781):1949–61. doi:10.1016/S0140-6736(11)
60135-9
7. Jakovljevic MB. The key role of the leading emerging BRIC markets in the
future of global health care. Ser J Exp Clin Res (2014) 15(3):139–43. doi:10.5937/
sjecr1403139J
8. WattNF, Gomez EJ,McKeeM.Global health in foreign policy – and foreign pol-
icy in health? Evidence from the BRICS. Health Policy Plan (2013) 2013:1–11.
doi:10.1093/heapol/czt063
9. Goldman S, Bloomberg. Goldman Sachs’s MIST Topping BRICs as Smaller
Markets Outperform. Available from: http://www.bloomberg.com/news/2012-
08-07/goldman-sachs-s-mist-topping-brics-as-smaller-markets-
outperform.html
10. GhaffarA, ReddyKS, SinghiM. Burden of non-communicable diseases in South
Asia. BMJ (2004) 328(7443):807–10. doi:10.1136/bmj.328.7443.807
11. Dans A, Ng N, Varghese C, Tai ES, Firestone R, Bonita R. The rise of chronic
non-communicable diseases in Southeast Asia: time for action. Lancet (2011)
377(9766):680–9. doi:10.1016/S0140-6736(10)61506-1
12. Jakovljevic MB. Resource allocation strategies in Southeastern European
health policy. Eur J Health Econ (2013) 14(2):153–9. doi:10.1007/
s10198-012-0439-y
13. Rahim A, Sibai A, Khader Y, Hwalla N, Fadhil I, Alsiyabi H, et al. Non-
communicable diseases in the Arab world. Lancet (2014) 383(9914):356–67.
doi:10.1016/S0140-6736(13)62383-1
14. Popkin BM, Horton S, Kim S, Mahal A, Shuigao J. Trends in diet, nutritional
status, and diet-related noncommunicable diseases in China and India: the
economic costs of the nutrition transition. Nutr Rev (2001) 59(12):379–90.
doi:10.1111/j.1753-4887.2001.tb06967.x
15. Kumagai N, Ogura S. Persistence of physical activity in middle age: a nonlinear
dynamic panel approach. Eur J Health Econ (2014) 15(7):717–35. doi:10.1007/
s10198-013-0518-8
16. BloomDE, Cafiero E, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S,
et al. The global economic burden of noncommunicable diseases (No. 8712).
Program on the Global Demography of Aging (2012). Available from: https:
//ideas.repec.org/p/gdm/wpaper/8712.html
17. Yang G, Kong L, ZhaoW, Wan X, Zhai Y, Chen LC, et al. Emergence of chronic
non-communicable diseases in China. Lancet (2008) 372(9650):1697–705.
doi:10.1016/S0140-6736(08)61366-5
18. Mahal A, Karan A, Engelgau M. The Economic Implications of Non-
Communicable Disease for India. Washington, DC: World Bank (2010).
Available from: https://openknowledge.worldbank.com/handle/10986/13649
[License: CC BY 3.0 Unported]
19. Boutayeb A. The double burden of communicable and non-communicable dis-
eases in developing countries. Trans R Soc Trop Med Hyg (2006) 100(3):191–9.
doi:10.1016/j.trstmh.2005.07.021
20. Alwan A. Global Status Report on Non-Communicable Diseases 2010. World
Health Organization (2011). Available from: http://www.who.int/nmh/
publications/ncd_report_full_en.pdf
21. Beaglehole R, Bonita R, Alleyne G, Horton R, Li L, Lincoln P, et al.
UN high-level meeting on non-communicable diseases: addressing four
questions. Lancet (2011) 378(9789):449–55. doi:10.1016/S0140-6736(11)
60879-9
22. Gwatkin DR, Guillot M, Heuveline P. The burden of disease among the
global poor. Lancet (1999) 354(9178):586–9. doi:10.1016/S0140-6736(99)
02108-X
23. Lee K, Chagas LC, Novotny TE. Brazil and the framework convention on
tobacco control: global health diplomacy as soft power. PLoS Med (2010)
7(4):e1000232. doi:10.1371/journal.pmed.1000232
24. Jakovljevic MB, Jovanovic M, Nikic K, Dejanovic SD, Radovanovi A, Pirkovic
I, et al. Acute alcohol detoxification costs in upper-middle income: Western
Balkans. J Health Behav Public Health (2011) 1(2):1–7.
25. Alwan A, MacLean DR, Riley LM, d’Espaignet ET, Mathers CD, Stevens
GA, et al. Monitoring and surveillance of chronic non-communicable
diseases: progress and capacity in high-burden countries. Lancet (2010)
376(9755):1861–8. doi:10.1016/S0140-6736(10)61853-3
26. WHOGlobal Coordination.Mechanism on the Prevention and Control of NCDs.
Available from: http://www.who.int/nmh/ncd-coordination-mechanism/
background/en/
27. Revill P, Sculpher M. Cost effectiveness of interventions to tackle non-
communicable diseases. BMJ (2012) 344:e609. doi:10.1136/bmj.d7883
28. CerqueiraMT, Cravioto A, Dianis N, GhannemH, Levitt N, YanN, et al. Global
response to non-communicable disease. BMJ (2011) 342:d3823. doi:10.1136/
bmj.d3823
29. Salomon JA, Carvalho N, Gutiérrez-Delgado C, Orozco R, Mancuso A, Hogan
DR, et al. Intervention strategies to reduce the burden of non-communicable
diseases in Mexico: cost effectiveness analysis. BMJ (2012) 344:e614. doi:10.
1136/bmj.e355
30. Rodin J, de Ferranti D. Universal health coverage: the third global health
transition? Lancet (2012) 380(9845):861–2. doi:10.1016/S0140-6736(12)
61340-3
31. Allotey P, Reidpath DD, Yasin S, Chan CK, de-Graft Aikins A. Rethinking
health-care systems: a focus on chronicity. Lancet (2011) 377(9764):450–1.
doi:10.1016/S0140-6736(10)61856-9
32. Boytsov S, Potemkina RA. Perspectives: preventive measures for public health
in Russian Federation. Eur Heart J (2014) 16(Suppl A):A84–6. doi:10.1093/
eurheartj/sut018
33. Jakovljevic M, Gutzwiller F, Schwenkglenks M, Milovanovic O, Rancic N,
Varjacic M, et al. Costs differences among monoclonal antibodies-based first-
line oncology cancer protocols for breast cancer, colorectal carcinoma and
non-Hodgkin’s lymphoma. J BUON (2014) 19(3):1111–20.
34. Sposato LA, Esnaola MM, Zamora R, Zurrú MC, Fustinoni O, Saposnik
G. Quality of ischemic stroke care in emerging countries the Argentinian
National Stroke Registry (ReNACer). Stroke (2008) 39(11):3036–41. doi:10.
1161/STROKEAHA.108.521062
35. Lazic Z, Gajovıc O, Tanaskovic I, Milovanovic D, Atanasijevic D, Jakovljevic
MB. GOLD stage impact on COPD direct medical costs in elderly. J Health
Behav Public Health (2012) 2(3):1–7.
36. Biorac N, Jakovljević MB, Stefanović D, Perović S, Janković S. Assessment of
diabetes mellitus type 2 treatment costs in the Republic of Serbia. Vojnosanit
Pregl (2009) 66(4):271–6. doi:10.2298/VSP0904271B
37. Jakovljevic M, Djordjevic N, Jurisevic M, Jankovic S. Evolution of Ser-
bian pharmaceutical market alongside socioeconomic transition. Expert Rev
Pharmacoecon Outcomes Res (2015) 15(3):1–10. doi:10.1586/14737167.2015.
1003044
38. Ranković A, Rančić N, Jovanović M, Ivanović M, Gajović O, Lazić Z, et al.
Impact of imaging diagnostics on the budget: are we spending too much?
Vojnosanit Pregl (2013) 70(7):709–11.
39. Jakovljević M, Ranković A, Rančić N, Jovanović M, Ivanović M, Gajović O,
et al. Radiology services costs and utilization patterns estimates in Southeastern
Europe – a retrospective analysis from Serbia. Value Health Reg Issues (2013)
2(2):218–25. doi:10.1016/j.vhri.2013.07.002
40. JakovljevicMB. Oncologymonoclonal antibodies expenditure trends and reim-
bursement projections in the emerging Balkan market. Farmeconomia Health
Econ Ther Pathw (2014) 15(1):27–32. doi:10.7175/fe.v15i1.909
41. Jakovljevic M, Zugic A, Rankovic A, Dagovic A. Radiation therapy remains the
key cost driver of oncology inpatient treatment. J Med Econ (2015) 18(1):29–36.
doi:10.3111/13696998.2014.971162
42. Jakovljevic MB. Health expenditure dynamics in Serbia 1995-2012. Hosp Phar-
macol (2014) 1(3):180–3.
43. Wang Q, Brenner S, Leppert G, Banda TH, Kalmus O, De Allegri M. Health
seeking behaviour and the related household out-of-pocket expenditure for
Frontiers in Public Health | www.frontiersin.org April 2015 | Volume 3 | Article 654
Jakovljevic and Milovanovic Non-communicable diseases in BRICS nations
chronic non-communicable diseases in rural Malawi.Health Policy Plan (2015)
30(2):242–52. doi:10.1093/heapol/czu004
44. Jakovljevic MB, Jovanovic M, Lesch OM. Accessibility and affordability
of alcohol dependency medical care in Serbia. Front Psychiatry (2014)
5:192. doi:10.3389/fpsyt.2014.00192
45. McGranahan G,Martine G.Urbanization and Development: Policy Lessons from
the BRICS Experience. London (2012). Available from: http://pubs.iied.org/
pdfs/10622IIED.pdf
46. Kickbusch I. BRICS’ contributions to the global health agenda. Bull World
Health Organ (2014) 92(6):463–4. doi:10.2471/BLT.13.127944
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Jakovljevic and Milovanovic. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Public Health | www.frontiersin.org April 2015 | Volume 3 | Article 655
